Twinrix® vaccination schedules among injecting drug users

被引:3
|
作者
Brim, Nancy
Zaller, Nickolas [1 ]
Taylor, Lynn E.
Feller, Ed
机构
[1] Brown Univ, Sch Med, Providence, RI 02912 USA
[2] Miriam Hosp, Providence, RI 02906 USA
关键词
hepatitis; IDU; Twinrix; vaccine; HEPATITIS-B VACCINATION; VIRUS VACCINATION; RAPID PROTECTION; YOUNG INJECTION; UNITED-STATES; RISK-FACTORS; A VIRUS; IMMUNOGENICITY; INFECTION; ADHERENCE;
D O I
10.1517/14712598.7.3.379
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Twinrix is the only licensed vaccine that provides dual protection against infection with hepatitis A virus (HAV) and hepatitis B virus (HBV). The standard vaccination schedule for Twinrix is 0, 1 and 6 months. However, many high-risk populations, such as injecting drug users (IDUs), do not complete the vaccination series and, thus, do not acquire sufficient immunity against HAV and HBV. Twinrix can be administered using an accelerated vaccination schedule of 0, 7 and 21 days, with a booster recommended at 12 months. This manuscript reviews the available literature on vaccinating IDUs against HAV and HBV. The authors conclude that there is insufficient evidence regarding whether the accelerated Twinrix HAV/HBV vaccination schedule would yield a greater number of IDUs protected against both HAV and HBV.
引用
收藏
页码:379 / 389
页数:11
相关论文
共 50 条
  • [21] Distribution of hepatitis C virus genotypes among injecting drug users in Lebanon
    Mahfoud, Ziyad
    Kassak, Kassem
    Kreidieh, Khalil
    Shamra, Sarah
    Ramia, Sami
    VIROLOGY JOURNAL, 2010, 7
  • [22] Measuring risk of HIV and HCV among injecting drug users in the Russian Federation
    Platt, Lucy
    Sutton, A. J.
    Vickerman, P.
    Koshkina, E.
    Maximova, S.
    Latishevskaya, N.
    Hickman, M.
    Bonell, C.
    Parry, J.
    Rhodes, T.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2009, 19 (04) : 428 - 433
  • [23] Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Transmission among Injecting Drug Users
    Alavian, Seyed-Moayed
    Mirahmadizadeh, Alireza
    Javanbakht, Mehdi
    Keshtkaran, Ali
    Heidari, Alireza
    Mashayekhi, Atefeh
    Salimi, Shima
    Hadian, Mohammad
    HEPATITIS MONTHLY, 2013, 13 (08) : 9
  • [24] A profile on HIV prevalence and risk behaviors among injecting drug users in Nigeria: Should we be alarmed?
    Eluwa, George I.
    Strathdee, Steffanie A.
    Adebayo, Samson B.
    Ahonsi, Babatunde
    Adebajo, Sylvia B.
    DRUG AND ALCOHOL DEPENDENCE, 2013, 127 (1-3) : 65 - 71
  • [25] Effect of age and frequency of injections on immune response to hepatitis B vaccination in drug users
    Tran, Thanh Q.
    Grimes, Carolyn Z.
    Lai, Dejian
    Troisi, Catherine L.
    Hwang, Lu-Yu
    VACCINE, 2012, 30 (02) : 342 - 349
  • [26] Injecting drug users: A stigmatised and stigmatising population
    Simmonds, Lesley
    Coomber, Ross
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2009, 20 (02) : 121 - 130
  • [27] Drug driving among injecting drug users in Sydney, Australia: prevalence, risk factors and risk perceptions
    Darke, S
    Kelly, E
    Ross, J
    ADDICTION, 2004, 99 (02) : 175 - 185
  • [28] Drug use and risk among regular injecting drug users in Australia: does age make a difference?
    Degenhardt, Louisa
    Kinner, Stuart A.
    Roxburgh, Amanda
    Black, Emma
    Bruno, Raimondo
    Fetherston, James
    Fry, Craig L.
    DRUG AND ALCOHOL REVIEW, 2008, 27 (04) : 357 - 360
  • [29] HIV outbreak among injecting drug users in the Helsinki region:: social and geographical pockets
    Kivela, Pia
    Krol, Anneke
    Simola, Susan
    Vaattovaara, Mari
    Tuomola, Pekka
    Brummer-Korvenkontio, Henrikki
    Ristola, Matti
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2007, 17 (04) : 381 - 386
  • [30] Current Situation and Trends in the Hepatitis C Virus Genotype Distribution among Injecting Drug Users in the Czech Republic
    Krekulova, L.
    Rehak, V
    Strunecky, O.
    Nemecek, V
    EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE, 2009, 58 (02): : 84 - 89